Loading clinical trials...

Sonazoid Enhanced Liver Cancer Trial for Early Detection | Clinical Trials | Clareo Health

UNKNOWNNA

Sonazoid Enhanced Liver Cancer Trial for Early Detection

NCT00822991•Kindai University

Summary

The aim of this study is to prove usefulness of contrast-enhanced ultrasound (CE-US) using Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound (B-mode US) for hepatitis virus related cirrhosis, who are defined as super high-risk patients for hepatocarcinogenesis,Furthermore, to analyze whether early detection of HCC by CE-US has a survival benefit than that by B-mode US.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age over 20
•2. HBV or HCV related liver cirrhosis
•3. No history of HCC
•4. Diagnosed as liver cirrhosis histologically or clinically Histologically confirmed by liver biopsy Confirmed by formula of diagnosing cirrhosis Radiological finding Finding of portal hypertension Platelet\<130,000
•5. Inpatient or outpatient
•6. Patients who signed a written informed consent form

Exclusion Criteria

•1. History of hypersensitivity to egg yolk
•2. Pregnant or lactating women and women who may be pregnant
•3. Severe liver dysfunction(AST, ALT,or BIL level \>10ULN
•4. Associated with HCC
•5. Patients receiving interferon
•6. Age under 20
•7. Judged by investigator not to be appropriate for inclusion in this study

Locations (1)

Kinki University School of Medicine, Department of Gastroenterology and Hepatology

Ōsaka-sayama, Osaka, Japan

Key Dates

Start Date

January 1, 2009

Primary Completion Date

December 1, 2019

Completion Date

December 1, 2019

Last Updated

December 30, 2010

Enrollment

760

ESTIMATED participants

Conditions

Hepatocellular CarcinomaLiver CirrhosisHepatitis BHepatitis C

Interventions

CE-US (Sonazoid™)

DEVICE

B-mode US

DEVICE

Contacts

Masatoshi Kudo, professor

CONTACT

+81-72-366-0221 m-kudo@med.kindai.ac.jp

Kazuomi Ueshima, lecturer

CONTACT

+81-72-366-0221 kaz-ues@med.kindai.ac.jp

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITING

Early Detection of Liver Cancer by QUS

NCT06345508

Hepatocellular CarcinomaLiver Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 30, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sonazoid Enhanced Liver Cancer Trial for Early Detection

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Early Detection of Liver Cancer by QUS

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer